The overarching goal of the Experimental Therapeutics Program (ETP) is to build a world-class academic center dedicated to bridging basic and translational science for the design of Innovative and Impactful cancer therapies. This program, originally named the Molecular Therapeutics program, was established in December 2004 and brings together an interdisciplinary group of 41 investigators from 15 different departments. Since the last funding cycle the research base of the Experimental Therapeutics Program increased 104% from $7,878,482 to $16,042,852 total annual direct support with a total annual direct research support, of which $3,683,482 is from the NCI. Over the last grant period, there were a total of 539 publications of the Experimental Therapeutics Program members, of which 9.3% are intra-programmatic and 21.1% are inter-programmatic. Led by Shaomeng Wang, Ph.D. and Judith Sebolt-Leopold, Ph,D., the ETP has a strong focus on the rational design and development of small-molecule targeted therapies and serves as a critical link between the basic science and clinical programs. The ETP has four major research themes: I) Identification of novel therapeutic agents and approaches that target key signaling pathways dysregulated in human cancer, II) Improvement of drug delivery systems to address tumor inaccessibility using nanotechnology platforms, III) Execution of lead optimization and preclinical biomarker studies to guide development candidate selection and clinical trial design, IV) Translation of these new cancer medicines and approaches into the clinic.
All of the research in the Experimental Therapeutics Program (ETP) has direct cancer relevance, Research objectives of Program investigators are directed toward the Identification of novel therapeutic agents and approaches for the treatment of cancer and translating these new cancer medicines in the clinic. To maximize ultimate clinical Impact, the ETP serves as a critical link between the basic science and clinical programs to enable the development of personalized therapies.
|Lee, Alice W; Ness, Roberta B; Roman, Lynda D et al. (2016) Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol 127:828-36|
|Mathewson, Nathan D; Jenq, Robert; Mathew, Anna V et al. (2016) Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17:505-13|
|Owen, John Henry; Graham, Martin P; Chinn, Steven B et al. (2016) Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head Neck 38 Suppl 1:E459-67|
|Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65|
|Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46|
|Boonstra, Philip S; Mukherjee, Bhramar; Gruber, Stephen B et al. (2016) Tests for Gene-Environment Interactions and Joint Effects With Exposure Misclassification. Am J Epidemiol 183:237-47|
|Amin, Nisar A; Malek, Sami N (2016) Gene mutations in chronic lymphocytic leukemia. Semin Oncol 43:215-21|
|Hardiman, Karin M; Ulintz, Peter J; Kuick, Rork D et al. (2016) Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest 96:4-15|
|Boonstra, Philip S; Taylor, Jeremy M G; Smolska-Ciszewska, Beata et al. (2016) Alpha/beta (Î±/Î²) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol 89:20150957|
|Di Girolamo, Daniela; Ambrosio, Raffaele; De Stefano, Maria A et al. (2016) Reciprocal interplay between thyroid hormone and microRNA-21 regulates hedgehog pathway-driven skin tumorigenesis. J Clin Invest 126:2308-20|
Showing the most recent 10 out of 1165 publications